Contaminated Blood and Blood Products

Diana Johnson Excerpts

Thursday 14th October 2010 Commons Chamber

[The Parliamentary Under-Secretary of State for Health (Anne Milton)]

Let me start by congratulating the hon. Member for Hackney North and Stoke Newington (Ms Abbott) on her new post. We have something in common, inasmuch as I worked in Hackney for most of my life before I entered politics.

This has been a moving debate and I, too, welcome this opportunity to discuss these issues and to air people’s situations openly in the House. The story of those who have been affected by contaminated blood and its products is a dreadful human tragedy. I wonder whether, but can only hope that, an expression of sympathy from me can go some way towards making a difference to those affected. I am deeply sorry about the events that led to the infection of people who were treated with blood products with HIV and hepatitis C.

We always welcome new knowledge, but with that knowledge often comes deep regret about events that happened in the past. If we only knew then what we know now. We should always make sure, individually and as Governments, that we have the humility to learn from our past. I thank hon. Members for raising so many issues—about the terrible loss of life, of course, and about stigma and the additional cost of things such as dentistry. Yes, I would happily meet a delegation of hon. Members and my door will be open during this period of review.

I shall do all I can, in the time and on the terms available, to make sure that people’s views on access to psychological support are heard. I shall not be able to deal with all the points that have been raised today, but officials will come back to hon. Members, who, if they have further questions, can always contact me.

[Diana R. Johnson (Kingston upon Hull North) (Lab)]

Will the Minister address an issue that has not been raised—the medical assessments that people on benefits now have to go through under the new welfare reform programme? Will she consider making representations to her colleagues in the Department for Work and Pensions about passporting this group of claimants so that they do not have to go through medical assessments again?

[Anne Milton]

The hon. Lady makes an important point that has crossed my mind already. I shall talk to colleagues and officials in the DWP to make sure that that issue is addressed.

It is important to put on record some relevant events. In the early 1960s, the life expectancy of someone with haemophilia was less than 40 years. In the early 1970s, the development of a revolutionary new treatment—clotting factor concentrates produced from large pools of human plasma—led to what was then considered an exciting new era of treatment. It offered the potential to extend significantly the length and quality of the lives of patients with haemophilia. The risk of viral transmission through blood and blood products was recognised at that time, particularly the risk of post-transfusion hepatitis. Generally though, the consensus within the scientific community was that the risk of using multiple donors was low and worth taking. Significantly, at that time, the Haemophilia Society said, in a bulletin published in September 1983, that

“the advantages of treatment far outweigh any possible risk”.

Sadly, we know how wrong that was. Tragically, the society was wrong and a devastating blow was dealt. The initial hope was ultimately replaced by the dreadful realisation that, although lives were extended, almost 5,000 patients with haemophilia in the UK and thousands more throughout the world had been infected with hepatitis C, HIV or indeed both.

Many of those people have since lost their lives to those conditions, and more continue to do so by the week, and we should pay tribute to the many campaigners who have died. I fully understand the sense of grievance and anger that people feel. I am not in that position, and it is impossible to know fully what it feels like, but I do understand some of it. I also know that for some time, whatever the Government do, sadly it will be far too little, far too late.

At the time, however, no other treatment was available. The UK blood supply and the only alternative, a product called cryoprecipitate, were both contaminated. The only real treatment, therefore, was no treatment at all, and that was the case not only in the UK, but in countries throughout the world. At the time, France, Germany, Japan and the United States all took a similar view, which was widely held by the scientific community throughout the world.

When those treatments were first introduced, we had a very different view also of the risks from hepatitis C. It was not until the mid-1980s that scientific and medical literature began to reflect increasing concern about the seriousness of disease associated with hepatitis C, and I, as somebody who was working as a nurse at the time, remember it well.